Related references
Note: Only part of the references are listed.Plasma cell leukaemia and other aggressive plasma cell malignancies
Taimur Sher et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Primary plasma cell leukemia and autologous stem cell transplantation
Mary B. Drake et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
Herve Avet-Loiseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
International Myeloma Working Group Consensus Statement Regarding the Current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma
Henk Lokhorst et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
Michele Cavo et al.
LANCET (2010)
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
Maria-Victoria Mateos et al.
LANCET ONCOLOGY (2010)
Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma
S. Kumar et al.
LEUKEMIA (2010)
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone
H. Avet-Loiseau et al.
LEUKEMIA (2010)
Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies
M. A. Dimopoulos et al.
LEUKEMIA (2010)
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13
Donna Reece et al.
BLOOD (2009)
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone
Prashant Kapoor et al.
BLOOD (2009)
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma
Twyla B. Bartel et al.
BLOOD (2009)
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
Bart Barlogie et al.
BLOOD (2008)
Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients:: A study of the intergroupe francophone du myelome
Olivier Decaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Role of genetics in prognostication in myeloma
Herve Avet-Loiseau
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2007)
Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma
Hong Chang et al.
LEUKEMIA RESEARCH (2007)
Magnetic resonance imaging in multiple myeloma: Diagnostic and clinical implications
Ronald Walker et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
John D. Shaughnessy et al.
BLOOD (2007)
Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion
V. Sagaster et al.
LEUKEMIA (2007)
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials
S. Jagannath et al.
LEUKEMIA (2007)
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma
Bart Barlogie et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
International staging system for multiple myeloma
PR Greipp et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients
R García-Sanz et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II
J Shaughnessy et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Share Paper
